Genetic Engineering & Biotechnology News

JUL 2017

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link:

Contents of this Issue


Page 38 of 45

Genetic Engineering & Biotechnology News | | JULY 2017 | 37 between human cell types [has been de- scribed in the literature]. 7 Selection of factors for transdifferentia- tion of one cell type to another is a trial-and- error process that is time-consuming and ex- pensive. An algorithm derived by this team can predict with great accuracy the factors needed for reprogramming, thus enabling the generation of large number of human cell types in the lab by cell reprogramming. 3D printing is everywhere these days and, it is advancing. Generation of engineered vascularized tissue remains a challenge, however. In a newer study, Jennifer Lewis' research group built on their earlier work and generated vascularized tissue of about 1 cm in thickness, thus, taking a step forward in tissue engineering and repair. 8 Also, 3D-printed ovaria have shown to be functional in a study with mice. 9 A biopros- thetic ovary was created using 3D-printed microporous scaffolds, restoring ovarian function in sterilized mice. Connected to this, the microrobotics field and its use in tissue engineering has evolved. Micro-sized smart building blocks contain- ing cells or drugs will be elements to build tissues. There has also been increased attention to the paracrine effects of mesenchymal stem cells via extracellular vesicles, but also via transfer of mitochondria. There are many articles coming out on this; this discovery could have clinical applications soon. Lastly, we have seen the derivation and differentiation of haploid human embryonic stem cells. 10 These cells may provide a novel tool to understand human development. Further, it may serve as a powerful tool for genetic screening to study the loss-of-func- tion mutation. These stem cells have poten- tial in transplantation and cell-based thera- pies [because they provide] a better genetic match. © 2017 MaxCyte, Inc. All Rights Reserved. Accelerating Your Discovery, Development and Manufacturing of Cell-based Medicines From concept to care, our delivery platform for cell engineering helps you harness the power of the cell. • The only cell engineering solution that scales from bench to bedside • Non-viral delivery platform for immuno- oncology, gene editing and regenerative medicine applications • Generate cell therapies with enhanced potency and efficacy • Increase safety with minimal toxicity • Clear regulatory pathway for streamlined development • 40+ partnered programs — making cell therapy a reality Any Cell. Any Molecule. Any Scale. ® Harness the power: Translational Medicine References 1. F.T. Moutos et al., "Anatomically shaped tissue-engineered cartilage with tunable and inducible anticytokine delivery for biological joint resurfacing," Proc. Natl. Acad. Sci. U.S.A. 113 (31) E4513–E4522, doi: 10.1073/ pnas.1601639113. 2. B. Zhang et al., "Biodegradable scaffold with built-in vasculature for organ-on-a-chip engineering and direct surgical anastomosis", Nat. Materials 15, 669–678 (2016), doi:10.1038/nmat4570. 3. S. Shukla et al., "Progenitor T-cell differentiation from hematopoietic stem cells using Delta-like-4 and VCAM-1", Nat. Methods 14(5), 531-538 (May 2017), doi: 10.1038/nmeth.4258. Epub Apr 10, 2017. 4. M.M. Pakulska, S. Miersch, and M.S. Shoichet, "Designer protein delivery: from natural occurring to engineered affinity controlled release systems", Science 351(6279):aac4750, doi: 10.1126/science.aac4750. 5. M.M. Pakulska, C.H. Tator, and M.S. Shoichet, "Local delivery of chondroitinase ABC with or without stromal cell-derived factor 1 promotes functional repair in the injured rat spinal cord", Biomaterials (accepted April 2017). 6. TissueGene, "TissueGene to Highlight Invossa, the World's First Cell-Mediated Gene Therapy for Degenerative Osteoarthritis, at JP Morgan Healthcare Conference", Press Release, tissuegene-to-highlight-invossa-the-worlds- first-cell-mediated-gene-therapy-for- degenerative-osteoarthritis-at-jp- morgan-healthcare-conference-300387715.html, accessed June 12, 2017. 7. O.J.L. Rackham et al., "A predictive computational framework for direct reprogramming between human cell types", Nat. Genetics 48, 331–335 (2016), doi:10.1038/ ng.3487. 8. D.B. Kolesky et al., "Three-dimensional bioprinting of thick vascularized tissue", Proc. Natl. Acad. Sci. U.S.A. 113 (12), 3179–3184, doi: 10.1073/pnas.1521342113. 9. M.M. Laronda et al., "A Bioprosthetic Ovary Created Using 3D Printed Microporous Scaffolds Restores Ovarian Function in Sterilized Mice", Nat. Commun. 8, 15261 (May 16, 2017). 10. I. Sagi et al., "Derivation and differentiation of haploid human embryonic stem cells", Nature 532, 107–111 (April 7, 2016), doi:10.1038/ nature17408. There is a greater emphasis on innovation in tissue engineering, which means making heroes of researchers who are serial inventors, company founders, and [those who] successfully translate technology [from the benchtop] into the clinic. —Dr. Weiss

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - JUL 2017